Biodegradable Polymeric Microparticles for Sustained Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those using timolol maleate, face challenges such as short duration of action, low bioavailability, and systemic side effects due to topical administration, necessitating frequent dosing and poor patient compliance, with existing sustained release formulations failing to provide effective drug delivery beyond 14 days.
Innovation Solution
Development of biodegradable polymeric microparticle compositions optimized for maximum drug loading and release, using polymers like PLGA and PLA to achieve sustained release of timolol maleate for over 90 days, administered subconjunctivally to minimize systemic absorption and enhance compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If topical administration of timolol maleate is used to treat glaucoma, then the drug can be applied easily to the eye, but the duration of action is short and requires frequent dosing
Solution Approach 1:
The drug is pre-loaded into biodegradable polymeric microparticles before administration, creating a reservoir that releases the drug over an extended period. This preliminary encapsulation action allows the drug to be administered once and remain effective for months, eliminating the need for frequent re-dosing while maintaining ease of administration through simple injection or implantation of the microparticle formulation
Solution Approach 2:
The invention changes the physical and chemical parameters of the drug delivery system by transitioning from free drug solution to microparticle-encapsulated formulation. This parameter change includes modifying the drug's release kinetics through polymer matrix control, changing the administration route from topical to injectable/implantable, and altering the duration of therapeutic effect from hours to months
2Ease of operation
If topical administration of timolol maleate is used to treat glaucoma, then the drug can be applied directly to the eye, but systemic absorption occurs causing adverse cardiopulmonary side effects
Solution Approach 1:
The biodegradable polymeric microparticles serve as an intermediary carrier between the drug and the ocular tissues. This intermediary system enables controlled local release of the drug at the administration site while preventing rapid systemic absorption. The polymer matrix acts as a barrier that modulates drug release kinetics, allowing the drug to exert its therapeutic effect locally before gradual degradation of the polymer releases the drug in a controlled manner
Solution Approach 2:
The invention extracts the drug from the aqueous environment that facilitates rapid systemic absorption and places it within a hydrophobic polymeric matrix. This extraction from the aqueous phase into the polymer matrix fundamentally changes the drug's absorption profile, reducing systemic bioavailability while maintaining ocular efficacy through sustained local release
3Duration of action of stationary object
If existing sustained release formulations are used, then the duration of drug delivery is extended, but the release period does not exceed 14 days
Solution Approach 1:
The invention employs composite materials consisting of biodegradable polymeric matrices (such as PLGA, PLA, or PCL) encapsulating timolol maleate. This composite structure combines the drug with biocompatible and biodegradable polymers that provide both structural integrity for sustained release and controlled degradation profiles. The composite nature allows tuning of release kinetics by selecting different polymer types, molecular weights, and degradation rates, achieving reliable drug delivery for 90 days or longer
Solution Approach 2:
The invention achieves extended duration by changing key parameters of the microparticle formulation, including polymer molecular weight, polymer composition ratios, microparticle size, and drug-to-polymer ratio. These parameter changes directly influence the degradation rate of the polymer matrix and the corresponding drug release kinetics, enabling sustained release profiles that extend from the 14-day limit of previous formulations to 90 days or longer
4Quantity of substance
If high weight percent drug loading is achieved in microparticles, then the amount of drug delivered is increased, but the release profile control becomes more challenging
Solution Approach 1:
The invention manages high drug loading (up to 50% or more drug by weight) while maintaining release profile control by adjusting critical parameters including polymer molecular weight, polymer composition (lactide:glycolide ratios in PLGA), microparticle size distribution, and drug-to-polymer ratio. These parameter changes allow the formulation to accommodate high drug concentrations without compromising the sustained release profile, as the polymer matrix structure and degradation kinetics can be tuned to match the drug loading level
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microparticle compositions provide a prolonged release of timolol maleate for up to 107 days, comparable to direct administration, reducing the frequency of dosing and minimizing systemic side effects, thereby improving patient compliance and treatment efficacy for glaucoma management.
Implementation Method 1
biodegradable polymeric microparticle compositions... providing sustained release over a prolonged period of time
Data Source
AI summary
Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing one or more diseases or disorders of the eye, and methods of making and using thereof, are described. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (IOP) in the eye. Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time.